Ubiquitin protein modification and signal transduction: Implications for inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 11, Issue 12, 2005, Pages 1097-1107

  Taylor, Cormac ^a   Jobin, Christian ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Hypoxia; Inflammation; Kinase; Signaling; Transcription factors; Ubiquitin

Indexed keywords

CORTICOSTEROID; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR; UBIQUITIN;

ENTERITIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION;

ANIMALS; CARRIER PROTEINS; HOMEOSTASIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATORY BOWEL DISEASES; NF-KAPPA B; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; UBIQUITIN;

EID: 27944487463     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000187577.26043.e5     Document Type: Review

References (119)

1. Ciechanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun. 1978;81:1100-1105.
2. Hershko A, Ciechanover A, Heller H, et al. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA. 1980;77:1783-1786.
3. Hershko A, Heller H, Elias S, et al. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem. 1983;258:8206-8214.
4. Finley D, Ciechanover A, Varshavsky A. Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85. Cell. 1984;37:43-55.
5. Chau V, Tobias JW, Bachmair A, et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science. 1989;243:1576-1583.
6. Pickart CM. Back to the future with ubiquitin. Cell. 2004;116:181-190.
7. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503-533.
8. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-663.
9. Pickart CM. Ubiquitin in chains. Trends Biochem Sci. 2000;25:544-548.
10. Bach I, Ostendorff HP. Orchestrating nuclear functions: ubiquitin sets the rhythm. Trends Biochem Sci. 2003;28:189-195.
11. Sigismund S, Polo S, Di Fiore PP. Signaling through monoubiquitination. Curr Top Microbiol Immunol. 2004;286:149-185.
12. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta. 2004;1695:189-207.
13. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46:705-716.
14. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17-26.
15. Chen FE, Ghosh G. Regulation of DNA binding by Rel/NF-κB transcription factors: structural views. Oncogene. 1999;18:6845-6852.
16. Burke JR. Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr Opin Drug Discov Devel. 2003;6:720-728.
17. Jobin C, Sartor RB. The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol. 2000;278:C451-C462.
18. Neurath MF, Becker C, Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut. 1998;43:856-860.
19. Rogler G, Brand K, Vogl D, et al. Nuclear factor kB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998;115:357-369.
20. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
21. Gerondakis S, Grumont R, Rourke I, et al. The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr Opin Immunol. 1998;10:353-359.
22. Liptay S, Bachern M, Hacker G, et al. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol. 1999;128:1361-1369.
23. Voll RE, Jimi E, Phillips RJ, et al. NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity. 2000;13:677-689.
24. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135-142.
25. Jobin C, Sartor RB. NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis. 2000;6:206-213.
26. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608.
27. Delhalle S, Blasius R, Dicato M, et al. A beginner's guide to NF-kappaB signaling pathways. Ann N Y Acad Sci. 2004;1030:1-13.
28. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxia-inducible factor. Cell Cycle. 2005;4:256-258.
29. Walmsley SR, Cadwallader KA, Chilvers ER. The role of HIF-1alpha in myeloid cell inflammation. Trends Immunol. 2005;26:434-439.
30. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1 alpha is essential for myeloid cell-mediated inflammation. Cell. 2003;112:645-657.
31. Hellwig-Burgel T, Stiehl DP, Wagner AE, et al. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res. 2005;25:297-310.
32. Kaelin WG. Proline hydroxylation and gene expression. Annu Rev Biochem. 2005;74:115-128.
33. Louis NA, Hamilton KE, Kong T, et al. HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J. 2005;19:950-959.
34. Leonard MO, Godson C, Brady HR, et al. Potentiation of glucocorticoid activity in hypoxia through induction of the glucocorticoid receptor. J Immunol. 2005;174:2250-2257.
35. Kong T, Eltzschig HK, Karhausen J, et al. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. Proc Natl Acad Sci USA. 2004;101:10440-10445.
36. Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol. 2003;56:209-213.
37. Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114:1098-1106.
38. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5:343-354.
39. Li Z, Wang D, Messing EM, et al. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep. 2005;6:373-378.
40. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002;295:858-861.
41. Brahimi-Horn C, Pouyssegur J. When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy. Crit Rev Oncol Hematol. 2005;53:115-123.
42. Thanos D, Maniatis T. NF-κB: a lesson in family values. Cell. 1995;80:529-532.
43. Gilmore TD, Morin PJ. The I κB protein: members of a multifunctional family. Trends Genet. 1993;9:427-433.
44. Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-681.
45. Arenzana-Seisdedos F, Turpin P, Rodriguez M, et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci. 1997;110:369-378.
46. DiDonato J, Mercurio F, Rosette C, et al. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol. 1996;16:1295-1304.
47. Regnier CH, Song HY, Gao X, et al. Identification and characterization of an IκB kinase. Cell. 1997;90:373-383.
48. Didonato JA, Hayakawa M, Rothwarf D, et al. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature. 1997;388:548-554.
49. Zandi E, Rothwarf DM, Belhase M, et al. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ necessary for IκB phosphorylation and NF-κB activation. Cell. 1997;91:243-252.
50. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science. 1997;278:860-866.
51. Woronicz JD, Gao X, Cao Z, et al. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science. 1997;278:866-869.
52. Delhasse M, Hayakawa M, Chen Y, et al. Positive and negative regulation of IκB kinase activity through IKKb subunit phosphorylation. Science. 1999;284:309-313.
53. Hatada EN, Krappmann D, Scheidereit C. NF-kappaB and the innate immune response. Curr Opin Immunol. 2000;12:52-58.
54. Hsu H, Shu H-B, Pan M-G, et al. TRADD-TRAF-2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299-308.
55. Hsu H, Huang J, Shu H-B, et al. TNF-dependent recruitement of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996;4:387-396.
56. McCarthy JV, Ni J, Dixit VM. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem. 1998;273:16968-16975.
57. Devin A, Cook A, Lin Y, et al. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF-2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity. 2000;12:419-429.
58. Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci. 2005;30:151-159.
59. Greenfeder SA, Nunes P, Kwee L, et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem. 1995;270:13757-13765.
60. Burns K, Martinon F, Esslinger C, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem. 1998;273:12203-12209.
61. Cao Z, Xiong J, Takeuchi M, et al. TRAF6 is a signal transducter for interleukin-1. Nature. 1996;383:443-446.
62. Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science. 1996;271:1128-1131.
63. Wesche H, Henzel WJ, Shillinglaw W, et al. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997;7:837-847.
64. Wu H, Arron JR. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays. 2003;25:1096-1105.
65. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, et al. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signaling. Nature. 1999;398:252-256.
66. Holtmann H, Enninga J, Kalble S, et al. The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation. J Biol Chem. 2001;276:3508-3516.
67. Karin M. How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene. 1999;18:6867-6874.
68. Yaron A, Gonen H, Alkalay I, et al. Inhibition of NF-κB cellular function via specific targeting of the IκB-ubiquitin ligase. EMBO J. 1997;16:6486-6494.
69. Yaron A, Hatzubai A, Davis M, et al. Identification of the receptor component of the IκB-ubiquitin ligase. Nature. 1998;396:590-594.
70. Maniatis T. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 1999;13:505-510.
71. Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev. 1995;9:1586-1597.
72. Alkalay I, Yaron A, Hatzubai A, et al. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1995;92:10599-10603.
73. Spencer E, Jiang J, Chen ZJ. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 1999;13:284-294.
74. Nakayama K, Hatakeyama S, Maruyama S, et al. Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci USA. 2003;100:8752-8757.
75. Orlowski RZ. Proteasome inhibitors in cancer therapy. Methods Mol Biol. 2005;301:339-350.
76. Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000;103:351-361.
77. Shi CS, Kehrl JH. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). J Biol Chem. 2003;278:15429-15434.
78. Wang C, Deng L, Hong M, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412:346-351.
79. Takaesu G, Kishida S, Hiyama A, et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell. 2000;5:649-658.
80. Kanayama A, Seth RB, Sun L, et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell. 2004;15:535-548.
81. Kishida S, Sanjo H, Akira S, et al. TAK1-binding protein 2 facilitates ubiquitination of TRAF6 and assembly of TRAF6 with IKK in the IL-1 signaling pathway. Genes Cells. 2005;10:447-454.
82. Takaesu G, Surabhi RM, Park KJ, et al. TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J Mol Biol. 2003;326:105-115.
83. Karin M, Delhase M. The I κB kinase (IKK) and NF-κB: key elements of proinflammatory signalling. Semin Immunol. 2000;12:85-98.
84. Abbott DW, Wilkins A, Asara JM, et al. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol. 2004;14:2217-2227.
85. Huang TT, Wuerzberger-Davis SM, Wu ZH, et al. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell. 2003;115:565-576.
86. Tang ED, Wang CY, Xiong Y, et al. A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. J Biol Chem. 2003;278:37297-37305.
87. Reiley W, Zhang M, Wu X, et al. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol. 2005;25:3886-3895.
88. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 2003;424:801-805.
89. Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature. 2003;424:793-796.
90. Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor- kappa B-dependent gene expression and apoptosis. Biochem Pharmacol. 2000;60:1143-1151.
91. Zhang SQ, Kovalenko A, Cantarella G, et al. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity. 2000;12:301-311.
92. Gon Y, Asai Y, Hashimoto S, et al. A20 inhibits toll-like receptor 2- and 4-mediated interleukin-8 synthesis in airway epithelial cells. Am J Respir Cell Mol Biol. 2004;31:330-336.
93. O'Reilly SM, Moynagh PN. Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. Biochem Biophys Res Commun. 2003;303:586-593.
94. Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000;289:2350-2354.
95. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430:694-699.
96. Evans PC, Ovaa H, Hamon M, et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J. 2004;378:727-734.
97. Lee TH, Shank J, Cusson N, et al. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem. 2004;279:33185-33191.
98. Gong Y, Chen C-M, Zheng Q-D, et al. The zing finger protein A20 interacts with p50 and regulates Nod-2- and RICK-induced NF-κB activation. Gastroenterology. 2003;124:A101.
99. Dohmen RJ. SUMO protein modification. Biochim Biophys Acta. 2004;1695:113-131.
100. Hay RT. SUMO: a history of modification. Mol Cell. 2005;18:1-12.
101. Johnson ES. Protein modification by SUMO. Annu Rev Biochem. 2004;73:355-382.
102. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell. 1998;2:233-239.
103. Comerford KM, Leonard MO, Karhausen J, et al. Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. Proc Natl Acad Sci USA. 2003;100:986-991.
104. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch. 2005;450:363-371.
105. An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol. 2005;25:7546-7556.
106. Haddad JJ, Harb HL. Cytokines and the regulation of hypoxia-inducible factor (HIF)-1alpha. Int Immunopharmacol. 2005;5:461-483.
107. Collier-Hyams LS, Zeng H, Sun J, et al. Cutting edge: salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF-kappa B pathway. J Immunol. 2002;169:2846-2850.
108. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB- alpha ubiquitination. Science. 2000;289:1560-1563.
109. Orth K, Xu Z, Mudgett MB, et al. Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease. Science. 2000;290:1594-1597.
110. Orth K. Function of the Yersinia effector YopJ. Curr Opin Microbiol. 2002;5:38-43.
111. Wicks SJ, Haros K, Maillard M, et al. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene. 2005.
112. Tanaka T, Soriano MA, Grusby MJ. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity. 2005;22:729-736.
113. Gao M, Labuda T, Xia Y, et al. Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science. 2004;306:271-275.
114. Rajendra R, Malegaonkar D, Pungaliya P, et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem. 2004;279:36440-36444.
115. Wong BR, Parlati F, Qu K, et al. Drug discovery in the ubiquitin regulatory pathway. Drug Discov Today. 2003;8:746-754.
116. Sakamoto KM, Kim KB, Kumagai A, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98:8554-8559.
117. Berleth ES, Kasperek EM, Grill SP, et al. Inhibition of ubiquitin-protein ligase (E3) by mono- and bifunctional phenylarsenoxides. Evidence for essential vicinal thiols and a proximal nucleophile. J Biol Chem. 1992;267:16403-16411.
118. Swinney DC, Xu YZ, Scarafia LE, et al. A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats. J Biol Chem. 2002;277:23573-23581.
119. Lawrence T, Bebien M, Liu GY, et al. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature. 2005;434:1138-1143.